Citigroup Inc Stoke Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 25,666 shares of STOK stock, worth $308,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,666

Previous 15,144 69.48%

Holding current value

$308,761

Previous $204,000 54.41%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$12.24 - $15.92 $128,789 - $167,510	10,522 Added 69.48%	25,666 $315,000
Q2 2024 Aug 12, 2024	BUY	$11.03 - $17.52 $106,748 - $169,558	9,678 Added 177.06%	15,144 $204,000
Q1 2024 May 10, 2024	BUY	$4.12 - $14.17 $6,155 - $21,169	1,494 Added 37.61%	5,466 $73,000
Q4 2023 Feb 09, 2024	BUY	$3.37 - $5.4 $11,363 - $18,208	3,372 Added 562.0%	3,972 $20,000
Q3 2023 Nov 09, 2023	SELL	$3.78 - $11.99 $33,521 - $106,327	-8,868 Reduced 93.66%	600 $2,000
Q2 2023 Aug 10, 2023	BUY	$7.93 - $13.82 $68,380 - $119,169	8,623 Added 1020.47%	9,468 $100,000
Q1 2023 May 11, 2023	SELL	$7.65 - $10.38 $1,507 - $2,044	-197 Reduced 18.91%	845 $7,000
Q4 2022 Feb 09, 2023	SELL	$7.07 - $15.69 $1,074 - $2,384	-152 Reduced 12.73%	1,042 $9,000
Q3 2022 Nov 10, 2022	SELL	$12.56 - $22.53 $18,011 - $32,308	-1,434 Reduced 54.57%	1,194 $15,000
Q2 2022 Aug 10, 2022	SELL	$10.36 - $23.93 $185,775 - $429,112	-17,932 Reduced 87.22%	2,628 $35,000
Q1 2022 May 12, 2022	SELL	$17.19 - $26.1 $588,482 - $893,507	-34,234 Reduced 62.48%	20,560 $433,000
Q4 2021 Feb 10, 2022	BUY	$18.11 - $30.72 $270,327 - $458,557	14,927 Added 37.44%	54,794 $1.32 Million
Q3 2021 Nov 10, 2021	BUY	$23.65 - $34.44 $942,854 - $1.37 Million	39,867 New	39,867 $1.01 Million

Others Institutions Holding STOK

# of Institutions

123

Shares Held

57.6M

Call Options Held

9.3K

Put Options Held

35.2K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $474M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account